Navigation Links
Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
Date:9/12/2007

rials, in which it was shown that E1-I.N.T.(TM) is safe to administer. Transition received FDA clearance to initiate exploratory Phase IIa clinical trials for E1-I.N.T.(TM) in both type 1 and type 2 diabetics. These two clinical trials evaluated the efficacy, safety and tolerability of a 28-day course of daily E1-I.N.T.(TM) treatments with a six-month follow-up.

In March, 2007, the Company announced positive unblinded interim safety, tolerability and efficacy data from these exploratory Phase IIa trials for type 1 and type 2 diabetes patients. In the type 1 diabetes study, 6 of 11 (54%) patients responded to E1-I.N.T.(TM) therapy, either by decreasing their average daily insulin usage by more than 20% or reducing their HbA1c levels by 1.2 to 2%. There were no responders among the placebo group.

On June 28, 2007, the Company announced final results from the exploratory Phase IIa E1-I.N.T.(TM) clinical trial. A 4-week therapy with E1-I.N.T.(TM) lead to sustained reductions in blood glucose levels for 6 months post-treatment in type 2 diabetes patients. In the E1-I.N.T.(TM) treated group of patients, the mean HbA1c level was reduced by 0.94% to 1.21% vs. baseline levels in months 2 to 6 post-treatment. More specifically, the mean HbA1c level among treated patients was reduced 0.43%, 0.94% (p<0.05), 1.09% (p<0.05), 1.12% (p<0.05), 1.21% (p<0.05), and 1.14% in months 1, 2, 3, 4, 5, and 6 post-treatment, respectively. In contrast, the mean HbA1c levels of the placebo group ranged from a reduction of 0.1% to an increase of 1.0% over the same period. In addition to the HbA1c reductions, the data demonstrated decreases in fasting blood glucose levels as well as improvements in glucose tolerance over a six month period following treatment with E1-I.N.T.(TM). Trends in increased insulin levels as measured with an oral glucose tolerance test were also observed, particularly in patients where the HbA1c levels decreased over 1% with E1-I.N.T.(TM) therapy. These data a
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Mans Transition from Foragers to Agriculturalist Led to Increase in Birth Rates
2. Rocky Transition to the Medicare Drug Program
3. Customized Post Operation Care Offers Patients a Smooth Transition to Patients into the Community
4. Mental Health - NHS Trust Commences Specialist Transition Service
5. Permanent Weight Loss Requires Transition to Healthy Eating
6. VBI Provides Potential Targets to Diabetes Therapeutics
7. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
8. PM announces a new health care order for India
9. Ramdoss Announces Introduction of RCH-II
10. Britain Announces Third Transfusion Related Mad Cow Case
11. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to ... Pharmacy Services at North Carolina State’s College of Veterinary ... Beal Award for Distinguished Volunteer Service—the organization’s highest award. ... contributions of volunteer experts to direct its work to ...
(Date:1/22/2015)... 2015 The City of West Hollywood hosted a ... commemorate the 42nd anniversary of the Supreme Court decision Roe v. ... 42 years since the Roe vs. Wade decision and the fight ... as ever,” said City of West Hollywood Councilmember Abbe Land. “We ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ has ... (PPHA). The PPHA's passion for others' well-being and shared ... treated for obstructive sleep apnea (OSA) has propelled them into ... the valley. The most recent plans for an event will ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... Public Can Directly Interact with Harvard Medical Doctors Via ... First Live Chat with Dr. Julie Silver, Harvard Medical ... 8 p.m. EDT, BOSTON, Oct. 28 Beginning ... top Harvard Medical doctor -without,leaving your laptop. Gather ...
... As October, Breast Cancer Awareness,Month, draws to ... Georgia (BCBSGa),understands that it is truly a year-round ... breast cancer care and awareness for its members.,The ... with breast,cancer and their physicians, has helped more ...
... on the Proposed Transfer of Listing of its ... H Shares from GEM to ... Shandong Luoxin Pharmacy,Stock Co., Ltd. (HKEx: 8058), announced its third ... a strong growth in turnover,and profit attributable to shareholders., ...
... Patients Lose 35% More Weight and Have Better Quality ... Surgery Itself, GAINESVILLE, Fla., Oct. 28 Those ... surgery lost 35,percent more weight the first year and ... according to new patient and bariatric surgeon surveys,conducted by ...
... health costs and medical crises fuel many foreclosures, bankruptcies ... and Deborah Krinsky of Magalia, Calif., have seen their ... And their health-care costs have put them in a ... and potential heart problems, Deborah,s connective tissue disorder and ...
... MPX Workstation and International Business Drive Top-Line Growth; ... Quarter of Profitability, WESTFORD, Mass., Oct. 28 ... manufacturer of a broad array of,light-based aesthetic treatment systems, ... ended September 30, 2008., Third-Quarter 2008 Financial Results, ...
Cached Medicine News:Health News:Gather and Harvard Health Publications Launch New Programs to Bring Harvard Medical School Doctors' Expertise Online 2Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 2Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 3Health News:Luoxin Announces 2008 Third Quarterly Results; Profit Attributable to Shareholders Surged 62.9% to Approximately RMB 138,141,000 2Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 2Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 3Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 4Health News:New National Patient and Surgeon Surveys Show Post-Surgical Care Critical to Optimal Weight Loss After Bariatric Surgery 5Health News:Medical Debt Sending Many Over Financial Brink 2Health News:Medical Debt Sending Many Over Financial Brink 3Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 2Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 3Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 4Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 5Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 6Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 7Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 8Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 9Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 10Health News:Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 11
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
(Date:1/23/2015)... BOSTON , January 23, 2015 ... development company, is delighted to announce that the Malcolm ... Miles Congreve (Vice President of Chemistry), Fiona ... Weir (Chief Executive Officer and co-founder) for the seminal ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... Nov. 7, 2011 Delcath Systems (NASDAQ: ... 2011 third quarter ended September 30, 2011.  Highlights for ... Research & Development:  Accelerated development of Generation ... has demonstrated significantly higher filtration efficiency of melphalan in ...
... Calif., Nov. 7, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, ... December 10-13, 2011, at the San Diego Convention Center ... being presented at ASH demonstrate carfilzomib,s potential activity along ...
Cached Medicine Technology:Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 2Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 3Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 4Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 5Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 6Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 7Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 8Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting 2Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting 3Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting 4Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting 5Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting 6
... AvantGard Low Binding 20l Barrier Tips. Low ... DNA and proteins bound to the tip. Most ... which means the focus is on liquid not ... focuses on low binding which reduces the binding ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
... Aerosol Resistant Tips offer a safe alternative ... are designed for applications such as PCR(a), ... addition, ART Tips are excellent for tissue ... studies. ART Tips prevent aerosol contaminants and ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
Medicine Products: